Moderna Inc reported Monday that its Omicron-tailored vaccines had produced a stronger immune response to the BA.4/5 subvariants during a mid-to late-stage study. This booster dose was given in comparison with its original shot.
Moderna claims that Omicron-tailored shots mRNA-1273.214 (and mRNA-1273.222) produced higher antibodies against BA.4/5 subvariants in the Omicron-tailored shots.
Moderna found that levels of neutralizing antibody responses to emerging subvariants BQ.1.1 dropped almost 5-fold compared to BA.4/5. However, the virus’s neutralizing activity remained “robust”.
Rival Pfizer Inc. and BioNTech SE, its German partner, stated earlier this month that their Omicron-tailored shot, which targets the BA.4/5 subvariants, produced a stronger antibody response in older adults after one month than the original shot.
Preclinical data shows that Omicron-tailored shots from Moderna and Pfizer have been approved in the United States. They are available for both adults and children as young as five years old. Nearly 31.4 million Americans had been vaccinated with the new shot by Nov. 9, and approximately 5.1 million were vaccinated in the week that ended.